The Present Situation and Clinical Topics of Ventricular Assist Device and Heart Transplantation in Japan

研究成果: ジャーナルへの寄稿評論記事

抄録

Surgical treatment for heart failure includes coronary artery bypass grafting to ischemic heart disease, valvular disease surgery such as mitral valvuloplasty, left ventricular restoration, ventricular assist device (VAD), and heart transplantation. In addition, HeartSheet which is regenerative medicine using autologous skeletal myoblast sheets has been started from the spring of 2016. Formal insurance reimbursement of implantable LVAD was obtained in April 2011, and the life prognosis of patients with severe heart failure improved markedly. However, the indication for implantable LVAD is limited to bridge use for heart transplantation. Implantable LVAD cannot be implanted in patients over 65 years old under health insurance because the adaptive age of heart transplantation in Japan is under 65 years old. It is a problem that the indication of implantable LVAD is identical to that of heart transplantation. Clinical trial of destination therapy is in progress for the purpose of optimizing the implantable LVAD indication. I strongly pray that VAD treatment including destination therapy (DT) and transplant medical treatment based on good intentions will be accepted socially as general treatment.

元の言語英語
ページ(範囲)213-222
ページ数10
ジャーナルFukuoka igaku zasshi = Hukuoka acta medica
107
発行部数12
出版物ステータス出版済み - 12 1 2016

Fingerprint

Heart-Assist Devices
Heart Transplantation
Japan
Heart Failure
Skeletal Myoblasts
Therapeutics
Regenerative Medicine
Health Insurance
Insurance
Treatment Failure
Coronary Artery Bypass
Myocardial Ischemia
Clinical Trials
Transplants

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

@article{0c14a1f3655b4d4d8cc58b7c8614c297,
title = "The Present Situation and Clinical Topics of Ventricular Assist Device and Heart Transplantation in Japan",
abstract = "Surgical treatment for heart failure includes coronary artery bypass grafting to ischemic heart disease, valvular disease surgery such as mitral valvuloplasty, left ventricular restoration, ventricular assist device (VAD), and heart transplantation. In addition, HeartSheet which is regenerative medicine using autologous skeletal myoblast sheets has been started from the spring of 2016. Formal insurance reimbursement of implantable LVAD was obtained in April 2011, and the life prognosis of patients with severe heart failure improved markedly. However, the indication for implantable LVAD is limited to bridge use for heart transplantation. Implantable LVAD cannot be implanted in patients over 65 years old under health insurance because the adaptive age of heart transplantation in Japan is under 65 years old. It is a problem that the indication of implantable LVAD is identical to that of heart transplantation. Clinical trial of destination therapy is in progress for the purpose of optimizing the implantable LVAD indication. I strongly pray that VAD treatment including destination therapy (DT) and transplant medical treatment based on good intentions will be accepted socially as general treatment.",
author = "Yoshihisa Tanoue and Akira Shiose",
year = "2016",
month = "12",
day = "1",
language = "English",
volume = "107",
pages = "213--222",
journal = "Fukuoka Acta Medica",
issn = "0016-254X",
publisher = "福岡医学会",
number = "12",

}

TY - JOUR

T1 - The Present Situation and Clinical Topics of Ventricular Assist Device and Heart Transplantation in Japan

AU - Tanoue, Yoshihisa

AU - Shiose, Akira

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Surgical treatment for heart failure includes coronary artery bypass grafting to ischemic heart disease, valvular disease surgery such as mitral valvuloplasty, left ventricular restoration, ventricular assist device (VAD), and heart transplantation. In addition, HeartSheet which is regenerative medicine using autologous skeletal myoblast sheets has been started from the spring of 2016. Formal insurance reimbursement of implantable LVAD was obtained in April 2011, and the life prognosis of patients with severe heart failure improved markedly. However, the indication for implantable LVAD is limited to bridge use for heart transplantation. Implantable LVAD cannot be implanted in patients over 65 years old under health insurance because the adaptive age of heart transplantation in Japan is under 65 years old. It is a problem that the indication of implantable LVAD is identical to that of heart transplantation. Clinical trial of destination therapy is in progress for the purpose of optimizing the implantable LVAD indication. I strongly pray that VAD treatment including destination therapy (DT) and transplant medical treatment based on good intentions will be accepted socially as general treatment.

AB - Surgical treatment for heart failure includes coronary artery bypass grafting to ischemic heart disease, valvular disease surgery such as mitral valvuloplasty, left ventricular restoration, ventricular assist device (VAD), and heart transplantation. In addition, HeartSheet which is regenerative medicine using autologous skeletal myoblast sheets has been started from the spring of 2016. Formal insurance reimbursement of implantable LVAD was obtained in April 2011, and the life prognosis of patients with severe heart failure improved markedly. However, the indication for implantable LVAD is limited to bridge use for heart transplantation. Implantable LVAD cannot be implanted in patients over 65 years old under health insurance because the adaptive age of heart transplantation in Japan is under 65 years old. It is a problem that the indication of implantable LVAD is identical to that of heart transplantation. Clinical trial of destination therapy is in progress for the purpose of optimizing the implantable LVAD indication. I strongly pray that VAD treatment including destination therapy (DT) and transplant medical treatment based on good intentions will be accepted socially as general treatment.

UR - http://www.scopus.com/inward/record.url?scp=85041268039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041268039&partnerID=8YFLogxK

M3 - Review article

VL - 107

SP - 213

EP - 222

JO - Fukuoka Acta Medica

JF - Fukuoka Acta Medica

SN - 0016-254X

IS - 12

ER -